Received Feb 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | AMVB044A | — |
a patient received a dose of Menveao with an unapproved diluent; a patient received a dose of Menveao with an unapproved diluent; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 16-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVB044A, expiry date 31-JUL-2025) for prophylaxis. Previously administered products included Menveo (1st dose on unknown date). On 15-JAN-2025, the patient received the 2nd dose of Menveo. On 15-JAN-2025, an unknown time after receiving Menveo, the patient experienced wrong solution used in drug reconstitution (Verbatim: a patient received a dose of Menveao with an unapproved diluent) and inappropriate dose of vaccine administered (Verbatim: a patient received a dose of Menveao with an unapproved diluent). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown. Additional Information: GSK receipt date: 17-JAN-2025 Other healthcare professional reported that a patient received a dose of Menveo with an unapproved diluent, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered.